Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.

Literature DB >> 881641

Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.

G Alván, M Lind, B Mellström, C von Bahr.

Abstract

Entities: Chemical

Mesh：

Substances：
Alprenolol

Year: 1977 PMID： 881641 DOI： 10.1007/bf01065395

Source DB: PubMed Journal: J Pharmacokinet Biopharm ISSN： 0090-466X

× No keyword cloud information.

22 in total

1. Proceedings: "First-pass" effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man.

Authors: C Bahr; G Alván; M Lind; B Mellström; V Sjöqvist
Journal: Acta Pharm Suec Date: 1974-12

2. Stoichiometric interaction of a beta-receptor blocking drug with fraction of liver cytochrome P-450 as a possible cause for its dose-dependent availability.

Authors: C von Bahr; H Vadi; A Norlin; P Moldéus
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1976-05

3. Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

Authors: D Perrier; M Gibaldi
Journal: J Pharmacol Exp Ther Date: 1974-10 Impact factor: 4.030

4. Steady-state plasma concentrations of alprenolol in man.

Authors: M D Rawlins; P Collste; M Frisk-Holmberg; M Lind; J Ostman; F Sjöqvist
Journal: Eur J Clin Pharmacol Date: 1974-08-23 Impact factor: 2.953

5. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors: G H Evans; D G Shand
Journal: Clin Pharmacol Ther Date: 1973 Jul-Aug Impact factor: 6.875

6. Relationship between dose and plateau levels of drugs eliminated by parallel first-order and capacity-limited kinetics.

Authors: T Tsuchiya; G Levy
Journal: J Pharm Sci Date: 1972-04 Impact factor: 3.534

7. Influence of route of administration on drug availability.

Authors: M Rowland
Journal: J Pharm Sci Date: 1972-01 Impact factor: 3.534

8. Plasma propranolol levels in adults with observations in four children.

Authors: D G Shand; E M Nuckolls; J A Oates
Journal: Clin Pharmacol Ther Date: 1970 Jan-Feb Impact factor: 6.875

9. Influence of the route of administration on the area under the plasma concentration-time curve.

Authors: P A Harris; S Riegelman
Journal: J Pharm Sci Date: 1969-01 Impact factor: 3.534

10. First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma.

Authors: G Alván; O Borga; M Lind; L Palmér; B Siwers
Journal: Eur J Clin Pharmacol Date: 1977-03-11 Impact factor: 2.953

12 in total

Review 1. Individual differences in the disposition of drugs metabolised in the body.

Authors: G Alvan
Journal: Clin Pharmacokinet Date: 1978 Mar-Apr Impact factor: 6.447

Review 2. Hepatic first-pass metabolism in liver disease.

Authors: T F Blaschke; P C Rubin
Journal: Clin Pharmacokinet Date: 1979 Nov-Dec Impact factor: 6.447

3. Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.

Authors: P Seideman; K O Borg; K Haglund; C Von Bahr
Journal: Br J Clin Pharmacol Date: 1987-03 Impact factor: 4.335

4. Pharmacokinetics of zimelidine in humans--plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine.

Authors: B L Love; R G Moore; J Thomas; S Chaturvedi
Journal: Eur J Clin Pharmacol Date: 1981 Impact factor: 2.953

Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.

1. Proceedings: "First-pass" effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man.

2. Stoichiometric interaction of a beta-receptor blocking drug with fraction of liver cytochrome P-450 as a possible cause for its dose-dependent availability.

3. Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

4. Steady-state plasma concentrations of alprenolol in man.

5. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

6. Relationship between dose and plateau levels of drugs eliminated by parallel first-order and capacity-limited kinetics.

7. Influence of route of administration on drug availability.

8. Plasma propranolol levels in adults with observations in four children.

9. Influence of the route of administration on the area under the plasma concentration-time curve.

10. First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma.

Review 1. Individual differences in the disposition of drugs metabolised in the body.

Review 2. Hepatic first-pass metabolism in liver disease.

3. Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.

4. Pharmacokinetics of zimelidine in humans--plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine.

5. A standard approach to compiling clinical pharmacokinetic data.

Review 6. First-pass elimination. Basic concepts and clinical consequences.

7. Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.

Review 8. Individual variation in first-pass metabolism.

Review 9. Clinical pharmacokinetics of prazosin.

10. First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma.